Gulisa Turashvili1, Monica Gonzalez-Loperena1, Edi Brogi1, Maura Dickler2, Larry Norton2, Monica Morrow3, Hannah Y Wen4. 1. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. weny@mskcc.org.
Abstract
BACKGROUND: Given the limited data, systemic treatment of male breast cancer has been extrapolated from female patients. The 21-gene recurrence score (RS) assay estimates the risk of distant recurrence and chemotherapy benefit in early-stage, ER+/HER2- female breast cancer. We assessed the association between RS and type of treatment in male breast cancer. METHODS: We identified male patients with ER+/HER2- breast cancer and available RS results treated at our institution in 2006-2016. We collected data on clinicopathologic features, treatment, and outcome. The Institutional Review Board approved the study. RESULTS: The study cohort consists of 38 male breast cancer patients with a median age of 70 years. Median tumor size was 1.6 cm, and 81.6% (31) were node-negative. RS was low (≤ 17) in 26 (68.4%) cases, intermediate (18-30) in 9 (23.7%) cases, and high (≥ 31) in 3 (7.9%) cases, comparable to that in female patients at our institution. All patients underwent total mastectomy, and one received radiotherapy. Thirty-four (89.5%) patients received adjuvant endocrine therapy, mostly tamoxifen (81.6%; 31). Five (13.2%) patients with intermediate or high RS were treated with adjuvant chemotherapy. No locoregional recurrence was observed, and one patient developed distant recurrence (median follow-up 34 months). CONCLUSIONS: The RS distribution in male breast cancers was similar to that in females treated at our institution. With limited follow-up, patients with low RS were spared chemotherapy and did not develop recurrence. Our results suggest that the RS may have a clinical utility in male breast cancer patients.
BACKGROUND: Given the limited data, systemic treatment of male breast cancer has been extrapolated from female patients. The 21-gene recurrence score (RS) assay estimates the risk of distant recurrence and chemotherapy benefit in early-stage, ER+/HER2- female breast cancer. We assessed the association between RS and type of treatment in male breast cancer. METHODS: We identified male patients with ER+/HER2- breast cancer and available RS results treated at our institution in 2006-2016. We collected data on clinicopathologic features, treatment, and outcome. The Institutional Review Board approved the study. RESULTS: The study cohort consists of 38 male breast cancerpatients with a median age of 70 years. Median tumor size was 1.6 cm, and 81.6% (31) were node-negative. RS was low (≤ 17) in 26 (68.4%) cases, intermediate (18-30) in 9 (23.7%) cases, and high (≥ 31) in 3 (7.9%) cases, comparable to that in female patients at our institution. All patients underwent total mastectomy, and one received radiotherapy. Thirty-four (89.5%) patients received adjuvant endocrine therapy, mostly tamoxifen (81.6%; 31). Five (13.2%) patients with intermediate or high RS were treated with adjuvant chemotherapy. No locoregional recurrence was observed, and one patient developed distant recurrence (median follow-up 34 months). CONCLUSIONS: The RS distribution in male breast cancers was similar to that in females treated at our institution. With limited follow-up, patients with low RS were spared chemotherapy and did not develop recurrence. Our results suggest that the RS may have a clinical utility in male breast cancerpatients.
Authors: Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark Journal: N Engl J Med Date: 2004-12-10 Impact factor: 91.245
Authors: J Albanell; A González; M Ruiz-Borrego; E Alba; J A García-Saenz; J M Corominas; O Burgues; V Furio; A Rojo; J Palacios; B Bermejo; M Martínez-García; M L Limon; A S Muñoz; M Martín; I Tusquets; F Rojo; R Colomer; I Faull; A Lluch Journal: Ann Oncol Date: 2011-06-06 Impact factor: 32.976
Authors: Foluso O Ademuyiwa; Austin Miller; Tracey O'Connor; Stephen B Edge; Mangesh A Thorat; George W Sledge; Ellis Levine; Sunil Badve Journal: Breast Cancer Res Treat Date: 2011-01-01 Impact factor: 4.872
Authors: Eleftherios P Mamounas; Qing Liu; Soonmyung Paik; Frederick L Baehner; Gong Tang; Jong-Hyeon Jeong; S Rim Kim; Steven M Butler; Farid Jamshidian; Diana B Cherbavaz; Amy P Sing; Steven Shak; Thomas B Julian; Barry C Lembersky; D Lawrence Wickerham; Joseph P Costantino; Norman Wolmark Journal: J Natl Cancer Inst Date: 2017-01-25 Impact factor: 13.506
Authors: Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Edith A Perez; John A Olson; JoAnne Zujewski; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; James N Atkins; Jeffrey L Berenberg; George W Sledge Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245
Authors: José Pablo Leone; Ariel Osvaldo Zwenger; Julián Iturbe; Julieta Leone; Bernardo Amadeo Leone; Carlos Teodoro Vallejo; Rohit Bhargava Journal: Breast Cancer Res Treat Date: 2016-04-02 Impact factor: 4.872
Authors: R Lewin; A Sulkes; T Shochat; D Tsoref; S Rizel; N Liebermann; D Hendler; V Neiman; I Ben-Aharon; E Friedman; S Paluch-Shimon; D Margel; I Kedar; R Yerushalmi Journal: Breast Cancer Res Treat Date: 2016-05-25 Impact factor: 4.872
Authors: Ida Johansson; Cecilia Nilsson; Pontus Berglund; Martin Lauss; Markus Ringnér; Håkan Olsson; Lena Luts; Edith Sim; Sten Thorstensson; Marie-Louise Fjällskog; Ingrid Hedenfalk Journal: Breast Cancer Res Date: 2012-02-14 Impact factor: 6.466
Authors: W Eiermann; M Rezai; S Kümmel; T Kühn; M Warm; K Friedrichs; A Schneeweiss; S Markmann; H Eggemann; J Hilfrich; C Jackisch; I Witzel; H Eidtmann; A Bachinger; S Hell; J Blohmer Journal: Ann Oncol Date: 2012-11-07 Impact factor: 32.976
Authors: Matthew G Davey; Ciara M Davey; Luis Bouz; Eoin Kerin; Carson McFeetors; Aoife J Lowery; Michael J Kerin Journal: Breast Date: 2022-04-28 Impact factor: 4.254